Menu

CONGRESS 2023 - From the laboratory to headlines. How to validate laboratory methods to screen and measure novel drugs

In the US, the death rate from drug overdoses more than tripled between 1999 and 2017, this was driven by increase use of opioids. This opioid epidemic had three phases: the first was dominated by prescription opioids such as oxycodone, the second by heroin, and the third by cheaper but more potent synthetic opioids such as fentanyl. Despite a few outbreaks of synthetic opioids (such as fentanyl analogues) causing death is particular geographic areas, the UK has not faced the same epidemic as the US. However, over the past 2-3 years the UK has seen an increase in the detection of 2-benzyl benzimidazole (‘nitazene’) type opioids. These are found mixed with heroin or purchased online, typically sold as oxycodone. This talk will give a brief overview of novel opioids, discuss the potential for harm and highlight the analytical strategies to develop validated assays to detect and measure both novel opioids and other novel psychoactive substances.

Download as vCalendar (for Microsoft Outlook etc.)

Import event to your Google Calendar

28th September 2023
Venue: The International Convention Centre (ICC), Birmingham
Learning outcomes

Delegates attending this presentation will understand:

  • How to develop methods for Liquid chromatography tandem mass spectrometry (LCMSMS) / Gas chromatography tandem mass spectrometry (GCMSMS)
  • An overview of validation
  • Problems with finding EQA for newly developed novel assays